Macau | Local branch of Confucius Institute operative by early 2018
| 10:00pm
Film Festival | Hunting Season wins the Best Film Award at IFFAM
| 09:28pm
Macau | Future uncertain for Canidrome dogs as deadline looms
| 09:17pm
Macau | Local hotel industry service is on top of the list in Asia - Hotelier Awards Director
| 06:58pm
Two astronauts, cosmonaut return from five-month ISS mission
| 06:43pm
Macau | Record-breaking land transaction in Macau SAR confirmed, William Kwan vendor in the deal
| 06:27pm
Macau | Gov't striving to complete internal legislative procedure for taxi regulations by Q1 2018 - Sonia Chan
| 06:21pm
Film Festival | Brazilian director and producer at IFFAM Project Market highlight feedback from industry
| 06:13pm
Seven decades in the making, EU set to sign defence pact
| 06:00pm
Macau Lifestyle | DFS Masters of Time luxury watch exhibition to be held until Feb. 28, 2018
| 05:53pm

MUST partner delays investment payment

Zhongzhi Pharmaceutical Holdings Limited has not yet financially invested in a joint venture with Macau University of Science and Technology Foundation

Traditional Chinese medicine group Zhongzhi Pharmaceutical Holdings Limited will inject MOP480,000 (US$59,945) into a joint venture with Macau University of Science and Technology (MUST) Foundation by June 30 this year, revealed the company’s 2016 annual report.
A subsidiary of the group, Zhongzhi Pharmaceutical and Grant Talent Development Limited established a joint venture with MUST IPO Group Limited – a trust company of MUST Foundation- and six individuals of the university group last October.
The consortium, named Scienwi Pharmaceutical Technology Company Limited, has a registered capital of MOP1 million, with Zhongzhi Pharmaceutical owning 48 per cent equity share as classified by its proposed investment of MOP480,000.
The company explained in the report that the payment had not yet been made due to ‘expected additional time needed’ for opening a bank account.

Herb earnings
Zhongzhi Pharmaceutical registered RMB53.9 million(MOP62.6 million/US$7.8 million) in profits in 2016, a 33.1 per cent year-on-year decrease due to an increase in advertising expenses, the annual report reads.
The company’s selling and distribution expenses primarily originated from its chain pharmacies, which increased 36.7 per cent yearly to RMB277.4 million in 2016. Nevertheless, the group’s revenues still managed to record a 6.2 per cent year-on-year increase to RMB730.5 million.
According to a statement by group chairman Lai Zhi Tian the Chinese Government has placed great emphasis upon regulating TCM, with the ‘Law on Chinese Medicines’ set to be enforced on July 1 this year.
The new legislation will allow TCM practitioners to obtain a licence to practise in hospitals and clinics in the same model as Western medicine professionals, while requiring regional governments to set up TCM clinics in public hospitals and clinics, the chairman notes.
Mr. Lai believes the new policies will stimulate the demand for herbal health supplements leading to a “sharp expansion” of the market.